Syntara

Syntara ROIC

The Return on Invested Capital (ROIC) of Syntara (SNT.AX) as of Nov 1, 2026 is -55.49 %. In the previous year, Return on Invested Capital (ROIC) was -49.18 % — a change of 12.82% (lower).

ROIC

-55.49 %

YoY

12.82%

Last updated:

Return on Invested Capital (ROIC) of Syntara is 2026 -55.49 % . Return on Invested Capital (ROIC) of Syntara was 2025 -49.18 % . It decreases by 12.82% lower compared to the previous year.

The Syntara ROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROIC
Date
ROIC
Jan 1, 2019
-91.23 AUD
Jan 1, 2020
-145.47 AUD
Jan 1, 2021
-32.40 AUD
Jan 1, 2022
-12.83 AUD
Jan 1, 2023
-97.91 AUD
Jan 1, 2024
-317.84 AUD
Jan 1, 2025
-49.18 AUD
Jan 1, 2026
-55.49 AUD
The Syntara ROIC history
YEARROICYoY
-55.49 %+12.82%
-49.18 %-84.53%
-317.84 %+224.61%
-97.91 %+663.39%
-12.83 %-60.41%
-32.40 %-77.73%
-145.47 %+59.44%
-91.23 %-375.17%
33.16 %-123.08%
-143.64 %+170.90%
-53.02 %-235.57%
39.11 %-122.37%
-174.83 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Syntara Stock analysis

What does Syntara do? Syntara Ltd generates revenue through the development and commercialization of pharmaceutical products targeting blood-related cancers and fibrotic diseases. Its lead candidate PXS-5505 is designed for myelofibrosis, a bone marrow cancer causing blood cell loss, while PXS-4728 serves as an SSAO/MAOB inhibitor for sleep disorders and neurodegenerative diseases. The company also markets Bronchitol for cystic fibrosis and Aridol as a lung function test, focusing on respiratory and fibrotic conditions. These products are developed through Syntara's drug discovery engine centered on amine oxidase inhibitors and pan-LOX inhibitors. The company's primary customers are healthcare providers and patients seeking treatments for myelofibrosis, fibrotic diseases, and respiratory conditions. Syntara's drug candidates target specific medical segments including oncology for blood cancers, neurology for Parkinson's disease progression, and respiratory care for cystic fibrosis. The firm advances its pipeline through clinical-stage development, leveraging its expertise in amine oxidase inhibitors to address unmet medical needs in these therapeutic areas. Syntara Limited, formerly Pharmaxis Ltd, operates as a clinical-stage drug development company with a focus on blood-related cancers. Its product portfolio includes PXS-5505 for myelofibrosis, PXS-4728 for neurodegenerative diseases, Bronchitol for cystic fibrosis, and Aridol for lung function testing. The company's revenue streams derive from the advancement of these drug candidates through clinical trials and potential future commercialization, with no indication of current commercial sales in the provided description. Syntara is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Syntara stock

Return on Invested Capital (ROIC) of Syntara is -55.49 % in 2026.

Return on Invested Capital (ROIC) of Syntara changed from -49.18 % to -55.49 %, representing a 12.82% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Invested Capital (ROIC) Syntara since 2006 – with annual values, charts, and detailed analysis.

ROIC measures how effectively a company uses its invested capital to generate profits. A ROIC above the cost of capital creates shareholder value.

ROIC = NOPAT / Invested Capital

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Invested Capital (ROIC)'s Syntara with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Invested Capital (ROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Invested Capital (ROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Syntara

All Key Metrics — Syntara